Drugs

, Volume 77, Issue 7, pp 777–784 | Cite as

Reslizumab in Eosinophilic Asthma: A Review

Adis Drug Evaluation

Abstract

Reslizumab (Cinqaero®; Cinqair®) is a humanized monoclonal antibody against interleukin-5 (IL-5), a cytokine mediator of eosinophilic airway inflammation. Reslizumab is indicated as an add-on treatment for severe eosinophilic asthma in adults, on the basis of data from the BREATH phase III clinical trial programme. In three double-blind BREATH studies of up to 52 weeks’ duration, adding intravenous reslizumab (3 mg/kg, once every 4 weeks) to the current asthma therapy of patients (aged 12–75 years) with eosinophilic asthma inadequately controlled with inhaled corticosteroids resulted in significant reductions in clinical asthma exacerbation frequency and significant improvements in lung function, asthma control and health-related quality of life relative to adding placebo. Pooled data from the two trials of 52 weeks’ duration indicated similar benefits with reslizumab across various patient subgroups, including patients with severe eosinophilic asthma. Reslizumab was generally well tolerated, with very few recipients experiencing severe or serious treatment-related adverse events. Moreover, in an open-label extension study, continued use of reslizumab for up to 2 years was associated with durable lung function benefit, without any new tolerability concerns. Thus, intravenous reslizumab extends the valuable add-on treatment options for adults with severe eosinophilic asthma inadequately controlled with standard therapies.

References

  1. 1.
    de Groot JC, Ten Brinke A, Bel EH. Management of the patient with eosinophilic asthma: a new era begins. ERJ Open Res. 2015;1(1). doi:10.1183/23120541.00024-2015.
  2. 2.
    Patterson MF, Borish L, Kennedy JL. The past, present, and future of monoclonal antibodies to IL-5 and eosinophilic asthma: a review. J Asthma Allergy. 2015;8:125–34.PubMedPubMedCentralGoogle Scholar
  3. 3.
    Greenfeder S, Umland SP, Cuss FM, et al. Th2 cytokines and asthma: the role of interleukin-5 in allergic eosinophilic disease. Respir Res. 2001;2(2):71–9.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Teva Pharmaceuticals Ltd. Reslizumab (Cinqaero®): summary of product characteristics. 2016. http://www.ema.europa.eu. Accessed 28 Mar 2017.
  5. 5.
    Teva Respiratory LLC. Cinqair® (reslizumab) injection, for intravenous use: US prescribing information. 2016. http://www.cinqair.com. Accessed 28 Mar 2017.
  6. 6.
    Egan RW, Athwal D, Bodmer MW, et al. Effect of Sch 55700, a humanized monoclonal antibody to human interleukin-5, on eosinophilic responses and bronchial hyperreactivity. Arzneimittelforschung. 1999;49(9):779–90.PubMedGoogle Scholar
  7. 7.
    Zhang J, Kuvelkar R, Murgolo NJ, et al. Mapping and characterization of the epitope(s) of Sch 55700, a humanized mAb, that inhibits human IL-5. Int Immunol. 1999;11(12):1935–44.CrossRefPubMedGoogle Scholar
  8. 8.
    Castro M, Zangrilli J, Wechsler ME, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med. 2015;3(5):355–66.CrossRefPubMedGoogle Scholar
  9. 9.
    Bjermer L, Lemiere C, Maspero J, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 study. Chest. 2016;150(4):789–98.CrossRefPubMedGoogle Scholar
  10. 10.
    Corren J, Weinstein S, Janka L, et al. Phase 3 study of reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts. Chest. 2016;150(4):799–810.CrossRefPubMedGoogle Scholar
  11. 11.
    Castro M, Mathur S, Hargreave F, et al. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med. 2011;184(10):1125–32.CrossRefPubMedGoogle Scholar
  12. 12.
    Kips JC, O’Connor BJ, Langley SJ, et al. Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study. Am J Respir Crit Care Med. 2003;167(12):1655–9.CrossRefPubMedGoogle Scholar
  13. 13.
    Egan RW, Athwahl D, Chou CC, et al. Pulmonary biology of anti-interleukin 5 antibodies. Mem Inst Oswaldo Cruz. 1997;92(Suppl 2):69–73.CrossRefPubMedGoogle Scholar
  14. 14.
    Jaworowicz D, Fiedler-Kelly J, Rabinovich-Guilatt L. The steady-state pharmacokinetic (PK) profile across a range of patient body weight categories supports weight-based dosing for intravenous (IV) reslizumab [abstract]. Am J Resp Crit Care Med. 2016;193(Meeting Abstracts):A1389.Google Scholar
  15. 15.
    Murphy K, Jacobs J, Bjermer L. Long-term safety and efficacy of reslizumab in patients with inadequately controlled, moderate-to-severe asthma and elevated blood eosinophil counts: an open-label extension study [abstract no. 1025]. Am J Respir Crit Care Med. 2015;191(Meeting Abstracts):A6455.Google Scholar
  16. 16.
    Bardin P, Murphy K, Garin M. Effect of reslizumab treatment on rescue systemic corticosteroid use in patients with asthma and elevated blood eosinophils: results from a pooled analysis of two phase 3, placebo-controlled trials [abstract no. A7783]. Am J Respir Crit Care Med. 2016;193(Meeting Abstracts).Google Scholar
  17. 17.
    Jacobs J, Murphy K, Bjermer L. Long-term effect of reslizumab on asthma-related quality of life (AQLQ) in asthma patients (pts) previously enrolled in reslizumab safety and efficacy studies [abstract no. P62]. Ann Allergy Asthma Immunol. 2015;115(5 Suppl):A57.Google Scholar
  18. 18.
    Weinstein SF, Germinaro M, Bardin P. Efficacy of reslizumab with asthma, chronic sinusitis with nasal polyps and elevated blood eosinophils [abstract no. 283]. J Allergy Clin Immunol. 2016;137(2 Suppl):AB86.Google Scholar
  19. 19.
    Bernstein DI, Mansfield L, Zangrilli J. Efficacy of reslizumab in older patients (≥65 years) with asthma and elevated blood eosinophils: results from a pooled analysis of two phase 3, placebo-controlled trials [abstract no. 284]. J Allergy Clin Immunol. 2016;137(2 Suppl):AB86.Google Scholar
  20. 20.
    Brusselle G, Germinaro M, Weiss S, et al. Reslizumab in patients with inadequately controlled late-onset asthma and elevated blood eosinophils. Pulm Pharmacol Ther. 2017;43:39–45.CrossRefPubMedGoogle Scholar
  21. 21.
    EMA. European public assessment report (EPAR): Cinqaero® (reslizumab). 2016. http://www.ema.europa.eu. Accessed 28 Mar 2017.
  22. 22.
    Data on file, Teva Pharmaceutical industries Ltd; 2017.Google Scholar
  23. 23.
    Scottish Intercollegiate Guidelines Network. SIGN 153—British guideline on the management of asthma. 2016. www.sign.ac.uk/pdf/SIGN153.pdf. Accessed 28 Mar 2017.
  24. 24.
    Global Initiative for Asthma. 2017 GINA Report, global strategy for asthma management and prevention. 2017. http://ginasthma.org. Accessed 28 Mar 2017.
  25. 25.
    Menzella F, Lusuardi M, Galeone C, et al. Tailored therapy for severe asthma. Multidiscip Respir Med. 2015;10(1):1.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Novartis Europharm Ltd. Xolair: summary of product characteristics. 2016. http://www.ema.europa.eu. Accessed 28 Mar 2017.
  27. 27.
    Genentech USA Inc and Novartis Pharmaceuticals Corporation. Xolair: US prescribing information. 2016. http://www.fda.gov. Accessed 28 Mar 2017.
  28. 28.
    Deeks ED. Mepolizumab: a review in eosinophilic asthma. BioDrugs. 2016;30(4):361–70.CrossRefPubMedGoogle Scholar
  29. 29.
    GlaxoSmithKline Trading Services Ltd. Nucala: summary of product characteristics. 2016. http://www.ema.europa.eu. Accessed 28 Mar 2017.
  30. 30.
    GlaxoSmithKline LLC. Nucala: US prescribing information. 2017. http://www.fda.gov. Accessed 28 Mar 2017.
  31. 31.
    Papathanassiou E, Loukides S, Bakakos P. Severe asthma: anti-IgE or anti-IL-5? Eur Clin Respir J. 2016;3:31813.CrossRefPubMedGoogle Scholar
  32. 32.
    National Institute for Health and Care Excellence. Appraisal consultation document. Reslizumab for treating eosinophilic asthma inadequately controlled by inhaled corticosteroids. 2016. https://www.nice.org.uk. Accessed 28 Mar 2017.
  33. 33.
    Whittington MD, McQueen RB, Ollendorf DA, et al. Assessing the value of mepolizumab for severe eosinophilic asthma: a cost-effectiveness analysis. Ann Allergy Asthma Immunol. 2017;118(2):220–5.CrossRefPubMedGoogle Scholar
  34. 34.
    Pelaia G, Vatrella A, Busceti MT, et al. Role of biologics in severe eosinophilic asthma—focus on reslizumab. Ther Clin Risk Manag. 2016;12:1075–82.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2017

Authors and Affiliations

  1. 1.SpringerAucklandNew Zealand
  2. 2.Department of Respiratory MedicineGhent University Hospital and Ghent UniversityGhentBelgium
  3. 3.Department of Epidemiology and Respiratory MedicineErasmus MCRotterdamThe Netherlands

Personalised recommendations